Our Technology

Adjuvance Technologies has developed the ability to synthesize saponin adjuvants such as QS-21, a critical component of the AS01 adjuvant developed by GSK. In addition, we have synthesized a novel analogue, TQL1055, with improved attributes compared to QS-21.

Competitive Advantage – SAPONEX and TQL1055